Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Senju Pharmaceutical Co., Ltd.

Hisayoshi Shimizu

Muneo Nonomura

Tomomichi Futo

Yasushi Mikura

Yasuyuki Suzuki

Hideo Terayama

Akihiro Nagai

Yasuo Doi

Mitsuaki Oshima

Kei Mukai

This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.

Producing a sustained-release preparation

A drug comprising either a peptide having the LH-RH action or an LH-RH antagonist is carried on an intrauterine contraceptive device (IUD) so as to be able to provide controlled release. Once the IUD is put in the uterus, the carried drug is gradually released over such a prolonged period of treatment time as, for example, several months to be continuously absorbed through the uterus mucosa or the vagina mucosa. This construction makes it possible to reduce the patient's pain and such a troublesomeness as frequent drug administration and continuously administer a necessary drug over a prolonged period of time while taking a contraceptive measures.

Pharmaceutical product for application to uterus mucosa

The hydrogel of the invention contains polyvinyl alcohol (a hydrogel support), and a high water-absorbent resin and/or a hydrophilic high molecular compound, which are capable of containing a large amount of water. The rate of evaporation of water from this hydrogel is slow. The hydrogel retains water for a long time and releases an active ingredient gradually. The hydrogel containing a pharmacologically active substance is useful as a pharmaceutical preparation.

Hydrogel

An injectable solution of a compound useful as an anti-ulcer agent of the formula; ##STR1## wherein R.sup.1 represents hydrogen, methoxy or trifluoromethyl group; R.sup.2 and R.sup.3, being the same as or different from each other, represent hydrogen or methyl group; and R.sup.4 represents a fluorinated C.sub.2 to C.sub.5 lower alkyl group, is provided by dissolving the compound in at least one of ethanol, propylene glycol and polyethylene glycol; or by dissolving the freeze-dried material of an alkaline aqueous solution of the compound in a mixture of an acidic substance and at least one of the above solvents.

Injectable solution containing a pyridyl methylsulfinylbenzimidazole

An antibiotic composition which comprises 7.beta.-[(Z)-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-methoxyiminoacetamide]-3 (1-imidazo[1,2-b]pyridazinium)-methyl-3-cephem-4-carboxylate hydrochloride and a pharmaceutically acceptable water-soluble basic substance, which is stable in storage and improved in solubility as well as free of local actions or hemolytic action.

Antibiotic composition

In the aqueous liquid preparation of this invention, which comprises a compound of the formula; ##STR1## wherein R is an alkyl having 1-6 carbon atoms, and at least one species of the solubilizers selected from the group consisting of polyvinylpyrrolidone, cyclodextrin and caffeine, the solubility of the compound in water can be heightened and the aqueous liquid prepared thereby can afford a desired stability and mitigate eye-irritation or nose-irritation.

Growing community of inventors

Takatsuki, Japan

Hisayoshi Shimizu